MVT-602 is an oligopeptide kisspeptin-1 receptor agonist and an investigational drug candidate for egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF).
More than 200 study participants have received treatment with MVT-602 in Phase 1 and Phase 2 clinical trials.
MVT-602 is not approved by the FDA
Clinical Trial Results
MVT-602 is not approved by the FDA.
In October 2018, we presented data from a Phase 1 trial of MVT-602 at the American Society of Reproductive Medicine (ASRM) Scientific Congress. Results of this trial showed that administration of MVT-602 in 24 healthy premenopausal women in the follicular phase produced a dose-related increase in LH and expected post-dose increases in FSH and estrogen. In June 2019, we presented data from a Phase 2a trial of MVT-602 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting. Results of this trial showed that the administration of MVT-602 produced an LH surge that approximated the natural mid-cycle LH surge and was associated with high rates of ovulation on ultrasound. Adverse events in these studies were similar between placebo and the MVT-602 groups with no apparent dose-related effects.
Recent News and Presentations
10 Feb 2020
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2019
10 Feb 2020
Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids